Prospective Assessment of Suicidal Ideation and Behavior: An Internet Survey of Pharmaceutical Sponsor Practices.

Objective: To survey the current approaches of clinical trial sponsors in prospective suicidal ideation and behavior assessments and challenges encountered. Design: An internet-based survey. Setting: Inclusion of prospective assessments of suicidal ideation and behavior in industry-sponsored clinica...

Descripción completa

Detalles Bibliográficos
Publicado en:Innovations in Clinical Neuroscience Vol. 11; no. 9/10; pp. 14 - 23
Autores principales: CHAPPELL, PHILLIP B., MAHABLESHWARKAR, ATUL R., ALPHS, LARRY D., BANGS, MARK E., BUTLER, ADAM, DuBRAVA, SARAH J., GREIST, JOHN H., LENDERKING, WILLIAM R., MUNDT, JAMES C., STEWART, MICHELLE
Formato: pictorial research tables/charts Journal Article
Publicado: Matrix Medical Communications, LLC Sep/Oct2014
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=100082479&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 100082479
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        21588333
        DAD5
      jtl: Innovations in Clinical Neuroscience
      issn: 21588333
      maglogo: N
    pubinfo:
      dt: Sep/Oct2014
      vid: 11
      iid: 9/10
      pid: 33670
      pub: Matrix Medical Communications, LLC
      place: West Chester, Pennsylvania
    artinfo:
      ui:
        100082479
        100082479
        103863079
        100082479
      ppf: 14
      ppct: 9
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Prospective Assessment of Suicidal Ideation and Behavior: An Internet Survey of Pharmaceutical Sponsor Practices.
      aug:
        au:
          CHAPPELL, PHILLIP B.
          MAHABLESHWARKAR, ATUL R.
          ALPHS, LARRY D.
          BANGS, MARK E.
          BUTLER, ADAM
          DuBRAVA, SARAH J.
          GREIST, JOHN H.
          LENDERKING, WILLIAM R.
          MUNDT, JAMES C.
          STEWART, MICHELLE
        affil: Pfizer, Inc., Groton, Connecticut.
      sug:
        subj:
          Suicidal Ideation Diagnosis
          Behavior
          Patient Assessment
          Pharmaceutical Companies
          Clinical Trials
          Human
          Prospective Studies
          Questionnaires
          Descriptive Statistics
          Internet
          Research Subjects
          Research Personnel
          Scales
          United States
      ab: Objective: To survey the current approaches of clinical trial sponsors in prospective suicidal ideation and behavior assessments and challenges encountered. Design: An internet-based survey. Setting: Inclusion of prospective assessments of suicidal ideation and behavior in industry-sponsored clinical studies were required following the release of the September 2010 United States Federal Drug Administration draft guidance. The International Society for CNS Clinical Trials and Methodology Suicidal Ideation and Behavior Assessment Workgroup conducted an online survey to understand industry practices and experiences in implementing suicidal ideation and behavior assessments in clinical trials. Participants: The survey was sent to 1,447 industry employees at 178 pharmaceutical companies. A total of 89 evaluable responses, representing 39 companies, were obtained. Measurements: A 30-item internet survey was developed asking about potential challenges and issues in implementing prospective suicidal ideation and behavior assessments. Results: Common factors in deciding whether to include suicidal ideation and behavior assessments in a clinical trial were psychiatric or neurologic drug product (95%); central nervous system activity (78%); disease (74%) and patient population (71%); and regulatory announcements and policies (74%).The most common challenges in implementing suicidal ideation and behavior assessments included crosscultural differences in acceptance of SIB assessments (40%); obtaining adequate baseline history (36.8%); obtaining translations (35%); investigator/rater discomfort with asking about suicidal ideation and behavior (32%); and inadequate training of raters to administer suicidal ideation and behavior ratings (30%). Conclusion: Among sponsors surveyed, the implementation rate of suicidal ideation and behavior assessment in central nervous systems studies is very high. Most have used the Columbia-Suicide Severity Rating Scale. Challenges regarding standardization of retrospective assessment timeframes and differing approaches to summarizing and analyzing suicidal ideation and behavior-related study data were frequently reported. These results suggest that inconsistent reports of suicidal ideation and behavior within study datasets may occur and that integration of data across studies remains a concern.
      pubtype: Academic Journal
      doctype:
        pictorial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N